Treatment for cancer patients has undergone a lot of technological advances over the decades. Thanks to the power of technology, people who had previously been consigned for death are now getting a lifeline. Clay Siegall is a scientist by profession who has put all his focus on targeted cancer therapies. He is a co-founder, Chairman of Board and the Chief Executive Officer of Seattle Genetics. Seattle Genetics is a biotech firm that has focused its energies on scientific research and innovation to develop therapeutic drugs for diseases like cancer. Siegall leadership has helped the firm substantially, and their first antibody-drug conjugates (ADC) called Adcetris recently got approval from FDA.
Clay Siegall graduated with a Bachelors of Science degree in Zoology from Maryland University and a postgraduate degree in Genetics from George Washington University. His interest in technology in medicine started long ago when he lost a close family member to cancer. He had seen the suffering of the patient due to the chemotherapy treatments and sought to improve on that. After his graduation, he worked with a few research companies before co-founding Seattle Genetics in 1998. Some other companies he worked for include National Institute of Health, National Cancer Institute, and Bristol-Myers Squibb Pharmaceuticals Research Institute. He has served in the board of directors of Mirna Therapeutics and is currently at Utragenyx Pharmaceuticals Inc and Washington Roundtable.
Seattle Genetics raised capital through an IPO where they collected more than $1.2 million. The company has faced success after the other since their product Adcetris became available in more than 70 countries. They recently acquired Cascadian Therapeutics and a whole manufacturing facility in North Creek area. Clay Siegall has won some awards like Pacific Northwest Ernst & Young Entrepreneur of the year 2012. He was also recently honored the John M. Fluke award for being the person who had demonstrated entrepreneurial spirit and community leadership. He credits the award to his relentless team at Seattle work hard to help patients. He is a published author of more than 70 publications. Siegall has proven to care for the people always and continues to assist in the development of cancer therapies.